# Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma

> **NCT06923475** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 150 (estimated)

## Conditions studied

- Extrahepatic Cholangiocarcinoma
- Perihilar Cholangiocarcinoma
- Distal Cholangiocarcinoma
- Resectable
- Borderline Resectable

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine, Cisplatin

## Key facts

- **NCT ID:** NCT06923475
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2028-11-06
- **Final completion:** 2028-11-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-04-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06923475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06923475, "Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06923475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*